Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study.

[1]  J. Clancy,et al.  Clinical Effectiveness of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients Homozygous for F508del-CFTR. , 2020, Annals of the American Thoracic Society.

[2]  P. Reix,et al.  Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  J. Clancy,et al.  Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[4]  D. Dorahy,et al.  Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  S. McColley,et al.  Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[6]  T. Corcoran,et al.  Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. , 2018, JCI insight.

[7]  B. Tümmler,et al.  Effects of Lumacaftor‐Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis , 2018, American journal of respiratory and critical care medicine.

[8]  S. Stanojevic,et al.  Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. , 2017, The Lancet. Respiratory medicine.

[9]  Linbo Liu,et al.  Ion Channels and Transporters in Lung Function and Disease Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy , 2016 .

[10]  A. Heinzmann,et al.  Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. , 2015, American journal of respiratory and critical care medicine.

[11]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[12]  Umer Khan,et al.  Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. , 2014, American journal of respiratory and critical care medicine.

[13]  J. Clancy,et al.  Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation , 2013, PloS one.

[14]  T. Corcoran,et al.  Multisite comparison of mucociliary and cough clearance measures using standardized methods. , 2013, Journal of aerosol medicine and pulmonary drug delivery.

[15]  Janet Stocks,et al.  Consensus statement for inert gas washout measurement using multiple- and single- breath tests , 2013, European Respiratory Journal.

[16]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[17]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[18]  J. Clancy,et al.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.

[19]  P. Negulescu,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[20]  ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. , 2005, American journal of respiratory and critical care medicine.